menu
    • menu

    Find Carbidopa manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 17
    Carbidopa

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 28860-95-9, Lodosyn, Carbidopa anhydrous, (s)-(-)-carbidopa, (s)-carbidopa, S-(-)-carbidopa
    Molecular Formula
    C10H14N2O4
    Molecular Weight
    226.23  g/mol
    InChI Key
    TZFNLOMSOLWIDK-JTQLQIEISA-N
    FDA UNII
    KR87B45RGH
    Carbidopa
    An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.
    1 2D Structure

    Carbidopa

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
    2.1.2 InChI
    InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
    2.1.3 InChI Key
    TZFNLOMSOLWIDK-JTQLQIEISA-N
    2.1.4 Canonical SMILES
    CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
    2.1.5 Isomeric SMILES
    C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
    2.2 Other Identifiers
    2.2.1 UNII
    KR87B45RGH
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Carbidopa, (r)-isomer

    2. Carbidopa, (s)-isomer

    3. Lodosin

    4. Lodosyn

    5. Methyldopahydrazine

    6. Mk 485

    7. Mk 486

    8. Mk-485

    9. Mk-486

    10. Mk485

    11. Mk486

    2.3.2 Depositor-Supplied Synonyms

    1. 28860-95-9

    2. Lodosyn

    3. Carbidopa Anhydrous

    4. (s)-(-)-carbidopa

    5. (s)-carbidopa

    6. S-(-)-carbidopa

    7. Alpha-methyldopahydrazine

    8. L-alpha-methyldopahydrazine

    9. N-aminomethyldopa

    10. Carbidopum

    11. Carbidopum [inn-latin]

    12. Carbidopa (anhydrous)

    13. S(-)-carbidopa

    14. Mk 486

    15. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid

    16. Carbidopa [inn]

    17. L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic Acid

    18. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic Acid

    19. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid

    20. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid

    21. Kr87b45rgh

    22. (alphas)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic Acid

    23. Chebi:39585

    24. 28860-95-9 (anhydrous)

    25. Ncgc00024596-05

    26. Hadrazino-alpha-methyldopa

    27. C-dopa

    28. 3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic Acid

    29. Smr000058235

    30. Ccris 5093

    31. Sr-01000597655

    32. Einecs 249-271-9

    33. Unii-kr87b45rgh

    34. Benzenepropanoic Acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-

    35. Alpha-hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic Acid

    36. L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic Acid

    37. L-alpha-methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic Acid

    38. Mfcd00069231

    39. Nd0611

    40. Tocris-0455

    41. C-126

    42. Dsstox_cid_2735

    43. Carbidopa [who-dd]

    44. Dsstox_rid_76707

    45. Dsstox_gsid_22735

    46. Lopac0_000382

    47. Schembl35084

    48. Mls000069628

    49. Mls002207014

    50. S-(-)-carbidopa Monohydrate

    51. Gtpl5159

    52. Carbidopa, L- Anhydrous

    53. Carbidopa Anhydrous [mi]

    54. Chembl1201236

    55. Dtxsid4022735

    56. Hms2089b12

    57. Hms3266a20

    58. Hms3411m13

    59. Hms3655g20

    60. Hms3675m13

    61. Hms3713l10

    62. Hms3884m14

    63. Hy-b0311

    64. Tox21_110910

    65. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propanoic Acid

    66. Bdbm50418773

    67. Nsc751137

    68. S1891

    69. Zinc19168887

    70. Akos015969657

    71. Benzenepropanoic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, (s)-

    72. Hydrocinnamic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, L-

    73. Ac-1676

    74. Ccg-204476

    75. Db00190

    76. Sdccgmls-0072919.p025

    77. Mls-0072919

    78. Smp1_000057

    79. Ncgc00024596-01

    80. Ncgc00024596-03

    81. Ncgc00024596-06

    82. Ncgc00024596-07

    83. Ncgc00024596-08

    84. As-16862

    85. Bc164279

    86. Mls-0072919.p013

    87. Cas-28860-95-9

    88. Eu-0100382

    89. Sw199080-2

    90. 60c959

    91. Ab00441332-05

    92. Ab00441332-06

    93. Ab00441332_07

    94. Ab00441332_08

    95. Sr-01000597655-1

    96. Sr-01000597655-3

    97. Sr-01000597655-5

    98. Sr-01000597655-9

    99. Brd-k78712176-001-07-5

    100. Benzenepropanoic Acid, A-hydrazino-3,4-dihydroxy-a-methyl-

    101. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinamic Acid

    102. (s)-?-hydrazino-?-methyl-?-(3,4-dihydroxyphenyl)propionic Acid

    103. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid

    104. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoicacid

    105. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic Acid

    106. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid Monohydrate

    107. Benzenepropanoic Acid, .alpha.-hydrazinyl-3,4-dihydroxy-.alpha.-methyl-, (.alpha.s)-

    108. Kinson; 3-(3,4-dihydroxy-phenyl)-2-hydrazino-2-methyl-propionic Acid

    109. 1426847-87-1

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 226.23 g/mol
    Molecular Formula C10H14N2O4
    XLogP3-2.2
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count4
    Exact Mass226.09535693 g/mol
    Monoisotopic Mass226.09535693 g/mol
    Topological Polar Surface Area116 Ų
    Heavy Atom Count16
    Formal Charge0
    Complexity261
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameCarbidopa
    PubMed HealthCarbidopa (By mouth)
    Drug ClassesAntiparkinsonian
    Drug LabelCarbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline...
    Active IngredientCarbidopa
    Dosage FormTablet
    RouteOral
    Strength25mg
    Market StatusPrescription
    CompanyAmerigen Pharms

    2 of 4  
    Drug NameLodosyn
    PubMed HealthCarbidopa (By mouth)
    Drug ClassesAntiparkinsonian
    Drug LabelCarbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro...
    Active IngredientCarbidopa
    Dosage FormTablet
    RouteOral
    Strength25mg
    Market StatusPrescription
    CompanyAton

    3 of 4  
    Drug NameCarbidopa
    PubMed HealthCarbidopa (By mouth)
    Drug ClassesAntiparkinsonian
    Drug LabelCarbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline...
    Active IngredientCarbidopa
    Dosage FormTablet
    RouteOral
    Strength25mg
    Market StatusPrescription
    CompanyAmerigen Pharms

    4 of 4  
    Drug NameLodosyn
    PubMed HealthCarbidopa (By mouth)
    Drug ClassesAntiparkinsonian
    Drug LabelCarbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro...
    Active IngredientCarbidopa
    Dosage FormTablet
    RouteOral
    Strength25mg
    Market StatusPrescription
    CompanyAton

    4.2 Drug Indication

    Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication. The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting. The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage. As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.

    5.2 MeSH Pharmacological Classification

    Antiparkinson Agents

    Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)

    Aromatic Amino Acid Decarboxylase Inhibitors

    Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. (See all compounds classified as Aromatic Amino Acid Decarboxylase Inhibitors.)

    Dopamine Agents

    Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)

    5.3 Absorption, Distribution and Excretion

    Absorption

    When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.

    Route of Elimination

    In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.

    Volume of Distribution

    The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.

    Clearance

    The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.

    5.4 Metabolism/Metabolites

    The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).

    5.5 Biological Half-Life

    The reported half-life of carbidopa is of approximately 107 minutes.

    5.6 Mechanism of Action

    Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

    Listed Suppliers

    read-more
    read-more

    01

    Malladi Drugs & Pharmaceuticals Lim...

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMalladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Malladi Drugs & Pharmaceuticals Ltd, founded in 1980 by Mr. M L N Sastry, is a leader in manufacturing ephedrine and pseudoephedrine salts. It is now the top API manufacturer in th...

    Malladi Drugs & Pharmaceuticals Ltd, founded in 1980 by Mr. M L N Sastry, is a leader in manufacturing ephedrine and pseudoephedrine salts. It is now the top API manufacturer in the cough and cold segment, with strong presence in antihistamines, anti-convulsants, anti-depressants, and anxiolytics. Malladi exports to around 60 countries, with over 85% revenue from exports, and its facilities are approved by FDA, EDQM, KFDA, TGA, and other agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Malladi

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    LGM Pharma

    U.S.A
    arrow
    CPhI North America
    Booth #730
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

    LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Bachem AG

    Switzerland
    arrow
    Peptide Therapeutics Forum 2026
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Contact Supplier Contact Supplier
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Bachem, with over 50 years of experience, supplies products for research, clinical development, and commercial use to pharmaceutical and biotechnology companies worldwide. It has e...

    Bachem, with over 50 years of experience, supplies products for research, clinical development, and commercial use to pharmaceutical and biotechnology companies worldwide. It has established itself as a leading, innovation-driven specialist in developing and manufacturing peptides and oligonucleotides. Headquartered in Switzerland with offices in Europe, the US, and Asia, Bachem is publicly listed on the SIX Swiss Exchange. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Bachem company banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Fermion Oy

    Finland
    arrow
    CPhI North America
    Booth #1629
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothWith Fermion, start the journey of your innovative API.

    Contact Supplier Contact Supplier
    Flag Finland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio inc...

    Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio includes over 30 generic APIs and more than 10 NCEs, with two manufacturing sites and R&D facilities in Finland. Fermion has expanded capabilities in HPAPI production. Drug product CMO services cover hormonal and non-hormonal semi-solids, cytotoxic oral solids, and packaging, supported by three manufacturing sites and one packaging center under Orion. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    fermion

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    TAPI Technology & API Services

    Israel
    arrow
    CPhI North America
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

    Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Maithri Drugs

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMaithri Drugs: Dedicated to your API needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...

    Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, antibiotics, ARVs, CNS, and cardiovascular segments. The company operates facilities approved by US FDA, EDQM, Health Canada, and WHO-GMP, supported by multiple global DMFs and Ecovadis recognition. Backed by strong R&D, global patents, and customer-focused practices, Maithri delivers high-quality APIs with regulatory excellence. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Divis Laboratories

    India
    PEGS Boston Summit
    Not Confirmed
    arrow

    Divis Laboratories

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Divis Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture for...

    Divis Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture for several Big Pharma companies under full cGMP. Customers regularly audit our facilities in areas of quality, EHS, business continuity etc. Unmatched Infrastructure:2 manufacturing sites. Both sites were successfully US-FDA Inspected No of DMFs 373 Pilot Plants30 Production Buildings39 Pharma Suites944 Reactors - 250 L to 30 KLTotal Capacity - 6676 M34 R&D Centers325 Scientists.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Everest Organics

    India
    PEGS Boston Summit
    Not Confirmed
    arrow

    Everest Organics

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : The Company was incorporated on 19.02.1993 to carry on the business of manufacturing of bulk drugs viz. Omeprazole,Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, etc...

    The Company was incorporated on 19.02.1993 to carry on the business of manufacturing of bulk drugs viz. Omeprazole,Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, etc., having its factory at Sadasivpet, Medak District, Hyderabad. The construction activities have started in the year 1994 and the commercial production of the company has started in 1996. Everest Organics has been making constant efforts to provide the best in products and services.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Otto Brandes

    Germany
    PEGS Boston Summit
    Not Confirmed
    arrow

    Otto Brandes

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Otto Brandes Gmbh was founded in 1923 and is an independent distributor of high quality Pharmaceutical Active Ingredients and excipients for the pharmaceutical industry. We regard ...

    Otto Brandes Gmbh was founded in 1923 and is an independent distributor of high quality Pharmaceutical Active Ingredients and excipients for the pharmaceutical industry. We regard ourselves as a service provider and focus on the customer`s interests. Our aim is to work together with you as a reliable and dependable partner, to achieve your requirements and objectives, enabling you to take a successful market position. Since 2015 we are a part of an internationally expanding group.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Shodhana Laboratories

    India
    PEGS Boston Summit
    Not Confirmed
    arrow

    Shodhana Laboratories

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Carbidopa

    About the Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most prestigious pharma co...

    Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most prestigious pharma companies. It is WHO-GMP, ISO 9001-2008 and ISO 14000:2004 certified. Shodhana develops quality products through cutting-edge research, expertise and the best drug manufacturing practices. Its manufacturing processes are as per ICH guidelines and cGMP-compliant. Shodhana also has a world-class R&D lab manned by a team of highly qualified scientists. Shodhana exports the highest-quality APIs and intermediates to markets across several countries.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 10MG;100MG

    USFDA APPLICATION NUMBER - 17555

    read-more

    DOSAGE - TABLET;ORAL - 25MG;100MG

    USFDA APPLICATION NUMBER - 17555

    read-more

    DOSAGE - TABLET;ORAL - 25MG;250MG

    USFDA APPLICATION NUMBER - 17555

    read-more

    DOSAGE - TABLET;ORAL - 25MG

    USFDA APPLICATION NUMBER - 17830

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 25MG...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 25MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19856

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 50MG...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 50MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19856

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 23....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 23.75MG;95MG

    USFDA APPLICATION NUMBER - 203312

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36.25MG;145MG

    USFDA APPLICATION NUMBER - 203312

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 48....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 48.75MG;195MG

    USFDA APPLICATION NUMBER - 203312

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 61....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 61.25MG;245MG

    USFDA APPLICATION NUMBER - 203312

    read-more

    DOSAGE - TABLET;ORAL - 12.5MG;200MG;50MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    DOSAGE - TABLET;ORAL - 18.75MG;200MG;75MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    DOSAGE - TABLET;ORAL - 25MG;200MG;100MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    DOSAGE - TABLET;ORAL - 31.25MG;200MG;125MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    DOSAGE - TABLET;ORAL - 37.5MG;200MG;150MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    DOSAGE - TABLET;ORAL - 50MG;200MG;200MG

    USFDA APPLICATION NUMBER - 21485

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Topical

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 28860-95-9 / Carbidopa API manufacturers, exporters & distributors?

    Carbidopa manufacturers, exporters & distributors 1

    18

    PharmaCompass offers a list of Carbidopa API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Carbidopa manufacturer or Carbidopa supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carbidopa manufacturer or Carbidopa supplier.

    API | Excipient name

    Carbidopa

    Synonyms

    28860-95-9, Lodosyn, Carbidopa anhydrous, (s)-(-)-carbidopa, (s)-carbidopa, S-(-)-carbidopa

    Cas Number

    28860-95-9

    Unique Ingredient Identifier (UNII)

    KR87B45RGH

    About Carbidopa

    An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.

    Carbidopa Monohydrate Manufacturers

    A Carbidopa Monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carbidopa Monohydrate, including repackagers and relabelers. The FDA regulates Carbidopa Monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carbidopa Monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Carbidopa Monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Carbidopa Monohydrate Suppliers

    A Carbidopa Monohydrate supplier is an individual or a company that provides Carbidopa Monohydrate active pharmaceutical ingredient (API) or Carbidopa Monohydrate finished formulations upon request. The Carbidopa Monohydrate suppliers may include Carbidopa Monohydrate API manufacturers, exporters, distributors and traders.

    click here to find a list of Carbidopa Monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Carbidopa Monohydrate USDMF

    A Carbidopa Monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Carbidopa Monohydrate active pharmaceutical ingredient (API) in detail. Different forms of Carbidopa Monohydrate DMFs exist exist since differing nations have different regulations, such as Carbidopa Monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Carbidopa Monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Carbidopa Monohydrate USDMF includes data on Carbidopa Monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carbidopa Monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Carbidopa Monohydrate suppliers with USDMF on PharmaCompass.

    Carbidopa Monohydrate JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Carbidopa Monohydrate Drug Master File in Japan (Carbidopa Monohydrate JDMF) empowers Carbidopa Monohydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Carbidopa Monohydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Carbidopa Monohydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Carbidopa Monohydrate suppliers with JDMF on PharmaCompass.

    Carbidopa Monohydrate KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Carbidopa Monohydrate Drug Master File in Korea (Carbidopa Monohydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carbidopa Monohydrate. The MFDS reviews the Carbidopa Monohydrate KDMF as part of the drug registration process and uses the information provided in the Carbidopa Monohydrate KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Carbidopa Monohydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carbidopa Monohydrate API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Carbidopa Monohydrate suppliers with KDMF on PharmaCompass.

    Carbidopa Monohydrate CEP

    A Carbidopa Monohydrate CEP of the European Pharmacopoeia monograph is often referred to as a Carbidopa Monohydrate Certificate of Suitability (COS). The purpose of a Carbidopa Monohydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carbidopa Monohydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carbidopa Monohydrate to their clients by showing that a Carbidopa Monohydrate CEP has been issued for it. The manufacturer submits a Carbidopa Monohydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carbidopa Monohydrate CEP holder for the record. Additionally, the data presented in the Carbidopa Monohydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carbidopa Monohydrate DMF.

    A Carbidopa Monohydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carbidopa Monohydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Carbidopa Monohydrate suppliers with CEP (COS) on PharmaCompass.

    Carbidopa Monohydrate WC

    A Carbidopa Monohydrate written confirmation (Carbidopa Monohydrate WC) is an official document issued by a regulatory agency to a Carbidopa Monohydrate manufacturer, verifying that the manufacturing facility of a Carbidopa Monohydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carbidopa Monohydrate APIs or Carbidopa Monohydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Carbidopa Monohydrate WC (written confirmation) as part of the regulatory process.

    click here to find a list of Carbidopa Monohydrate suppliers with Written Confirmation (WC) on PharmaCompass.

    Carbidopa Monohydrate NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carbidopa Monohydrate as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Carbidopa Monohydrate API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Carbidopa Monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Carbidopa Monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carbidopa Monohydrate NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Carbidopa Monohydrate suppliers with NDC on PharmaCompass.

    Carbidopa Monohydrate GMP

    Carbidopa Monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Carbidopa Monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Carbidopa Monohydrate GMP manufacturer or Carbidopa Monohydrate GMP API supplier for your needs.

    Carbidopa Monohydrate CoA

    A Carbidopa Monohydrate CoA (Certificate of Analysis) is a formal document that attests to Carbidopa Monohydrate's compliance with Carbidopa Monohydrate specifications and serves as a tool for batch-level quality control.

    Carbidopa Monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each Carbidopa Monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Carbidopa Monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Carbidopa Monohydrate EP), Carbidopa Monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carbidopa Monohydrate USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search